KYAN Technologies: Difference between revisions

Line 13:

==Technology==

KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ ~~differnt~~ cancer types.

KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ different cancer types.

The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models<ref>{{Cite web |title=Translational Biobank |url=https://kyantechnologies.com/translational-biobank/ |access-date=2025-12-20 |website=KYAN Technologies |language=en}}</ref>.

==Traction==

Line 22:

Line 24:

==Funding==

~~Describe the startup's~~ funding ~~history here~~. ~~Include investors in the table below~~.{{Startup/Funding history}}

KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web |last=Chong |first=Jinn Xiung |title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round |url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round |url-status=live}}</ref>.{{Startup/Funding history}}

== See also ==

@@ Line 13: / Line 13: @@
 ==Technology==
-KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ differnt cancer types.
+KYAN's technology uses fresh patient tissues, a 12-drug panel sensitivity test, and KYAN's AI-based platofrm to predict patient drug sensitivity for clinical decision support. The startup claims that this solution has >80% clinical accuracy<ref>{{Cite web |title=Optim.AI™ for Clinicians |url=https://kyantechnologies.com/optimai-clinical-decision-support/ |access-date=2025-12-20 |website=KYAN Technologies |language=en-US}}</ref> across 20+ different cancer types.
+The platform is also used for drug research. KYAN's biobank currently has approximately 100 clinically annotated models<ref>{{Cite web |title=Translational Biobank |url=https://kyantechnologies.com/translational-biobank/ |access-date=2025-12-20 |website=KYAN Technologies |language=en}}</ref>.
 ==Traction==
@@ Line 22: / Line 24: @@
 ==Funding==
-Describe the startup's funding history here. Include investors in the table below.{{Startup/Funding history}}
+KYAN Technologies raised US$5 million in pre-Series A funding from lead investor [[Altara Ventures]] in October 2022<ref>{{Cite web |last=Chong |first=Jinn Xiung |title=Biotech Startup Kyan Therapeutics Closes US$5m Oversubscribed Pre-Series A Round |url=https://www.tatlerasia.com/gen-t/leadership/biotech-startup-kyan-therapeutics-raises-us5-million-pre-series-a-round |url-status=live}}</ref>.{{Startup/Funding history}}
 == See also ==